BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure, announced today that its proprietary ‘PICM-19’ liver stem cell line is onboard the Space Shuttle “Endeavour” as part of a scientific experiment to investigate the differentiation and function of stem cells in space. The research is being performed under the International Space Station National Laboratory initiative.
